Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

  • In development
  • GID-TA11504
  • Expected publication date: 

Documents

Documents created during the development process.

Invitation to participate

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6310